LAS VEGAS, Oct. 28, 2019 /PRNewswire/ — AEVOLVE, a medical innovation platform, is a platinum sponsor of the second annual World Crypto Conference (WCC), which will attract thousands of digital currency and blockchain technology enthusiasts to the Las Vegas strip October 29 through 31, 2019.
Burdened by declining productivity and innovation, biopharma is seeking new ways of financing its growing needs. According to the Tufts Center for the study of Drug Development (CSDD), the cost to develop a new prescription drug is pegged at $2.6 billion. This marks a 145% increase from 2003 estimates, according to an article republished on Scientific American.
Aevolve, a Zurich-based healthtech company, has announced the filing of the first crypto token to be offered in a tracker certificate for subscription through the SIX Swiss Exchange.
In recent years, there has been some good news for many of the 30 million people in the U.S. diagnosed with a rare disease, in the form of long-awaited treatment for a number of specific conditions — but this progress has come at a staggering cost for these prescription medications. Fortunately, a new company focusing on life sciences — AEVOLVE AG — has a plan to support medical research that will benefit millions of others with rare diseases, without the alarming costs that are currently associated with drugs of this kind.
Rogelio Santos, Jr., CEO of Aevolve, a new platform dedicated to supporting innovative medical research, recently commented on the disturbing gap that exists between the millions of people who have been diagnosed with a rare disease and the life-saving medical treatment they are currently lacking. “Shockingly, 95% of all rare diseases today have absolutely no treatment.
